Psilocybin
Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer Patients
Reset Pharma is specifically honing in on the plight of cancer patients.
The post Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer…
Filament Health (OTCQB: FLHLF) has inked a licensing deal with biotech firm Reset Pharmaceuticals Inc. to test a psychedelic-based drug for treating a severe form of emotional distress.
Under the agreement, Filament will license its botanical psilocybin drug candidate, PEX010, to Reset Pharma for a phase 2 clinical trial.
“Clinical trial data indicates that psilocybin may be effective in treating demoralization syndrome,” said Jan-Anders Karlsson, co-founder and interim CEO of Reset Pharma.
While there’s growing interest in psychedelics as potential treatments for various mental health conditions, Reset Pharma is specifically honing in on the plight of cancer patients who grapple with intense feelings of demoralization, risking suicide, and currently lacking effective treatments.
“We believe that demoralization syndrome is a complex and under-examined area of study,” Filament CEO Benjamin Lightburn said in a statement. “We are thrilled to develop a partnership with Reset Pharma and look forward to the advancement of our drug candidate in this important field.”
Multiple other entities have already licensed Filament’s PEX010 for clinical trials, looking to address issues such as opioid addiction and alcohol-related disorders.
The post Reset Pharma Licenses Filament Drug to Combat Demoralization in Cancer Patients appeared first on Green Market Report.
psilocybin psychedelic psychedelics deal filament health filament
-
Psilocybin1 week agoPsychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics6 days agoCompass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics6 days agoCybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics5 days agoFreedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics5 days agoBehold! A New Mushroom Emoji Has Arrived!
-
Law & Regulation4 days agoCompass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Ketamine5 days agoDEA poised to move cannabis to Schedule III
-
Psychedelics5 days ago
Behold! A New Mushroom Emoji Has Arrived!